Nadofaragene Firadenovec Clinical Trials
4 recruitingDrug
Phase 33Phase 11Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled66 locationsNCT06545955
Recruiting
Phase 1Phase 2
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Low-grade Upper Tract Urothelial Carcinoma
Ferring Pharmaceuticals20 enrolled7 locationsNCT06668493
Recruiting
Phase 3
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center125 enrolled1 locationNCT06929286